Navigation Sciences

Executive Summary

Navigation Sciences is a private medical device company developing the NaviSci System, a surgical navigation and robotic platform designed for minimally invasive cancer surgery. The system focuses on real-time margin measurement to enable precise, tissue-conserving removal of soft tissue tumors, with an initial application in early-stage lung cancer surgery. Founded in 2016 and headquartered in San Jose, California, the company is at an early developmental stage, with no disclosed funding, FDA approvals, or commercial products to date. Its technology aims to address a critical unmet need in oncology by providing surgeons with intraoperative feedback on tumor margins, potentially reducing recurrence rates and preserving healthy tissue. While the company has not publicly announced clinical trials or partnerships, its platform could represent a significant advancement in surgical oncology if successfully developed and validated. The competitive landscape includes established players in surgical navigation and robotics, but Navigation Sciences' specific focus on real-time margin assessment may offer differentiation. Given the early stage, the company faces substantial technical, regulatory, and commercial risks. However, the growing demand for precision in cancer surgery and the potential for a novel solution warrant monitoring. The conviction score is moderate, reflecting the promise of the technology tempered by the lack of tangible milestones and the long development pathway typical for medical devices.

Upcoming Catalysts (preview)

• Q2 2027Initiation of First-in-Human Clinical Trial30% success
• Q4 2026FDA Breakthrough Device Designation50% success
• Q3 2026Series A Funding Round40% success